Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

India — Drugs Controller General of India

Tracked across 9 events · 327 articles · First seen Dec 27, 2025 · Last active Sep 24, 2026

Sentiment
8
Attention
6
Events
9
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 20
Regulatory
Impact: The India — Drugs Controller General of India has intensified regulatory surveillance on GLP-1 weight-loss drugs to prevent unauthorized sales and misuse, issuing advisories and conducting inspections.
Mar 24, 2026 · 11 articles
0 0
Domestic
Impact: The position gains a new leader, Alka Nangia Arora, who will direct defence financial management and audit functions.
Aug 01, 2026 · 6 articles
4 0
Regulatory
Impact: DCGI granted market authorization for QDENGA, marking the first dengue vaccine approval in India. This decision reflects the regulator's role in advancing public health.
Jul 20, 2026 · 93 articles
4 50
Regulatory
Impact: Granted regulatory approval, demonstrating its role in facilitating innovative pharmaceutical products in India.
Aug 20, 2026 · 6 articles
2 5
Tech
India's India — Drugs Controller General of India (DCGI) has approved an allogeneic bone marrow-derived mesenchymal stem cell therapy for knee osteoarthritis, marking the first time such an approved regenerative therapy enters clinical practice in…
Impact: The DCGI approved the stem cell therapy, enabling its clinical use and demonstrating regulatory support for advanced regenerative medicines in India.
Sep 10, 2026 · 6 articles
4 0
Domestic
Impact: The India — Drugs Controller General of India released the monthly accounts data, providing transparency on India's fiscal deficit, receipts, and expenditures.
Mar 30, 2026 · 6 articles
2 0
Regulatory
Impact: DCGI approval is awaited for resumption of Vivos' clinical trials in India and for a formal Phase I/II trial.
Jul 27, 2026 · 7 articles
4 0
Regulatory
Impact: The India — Drugs Controller General of India was informed by Indian Immunologicals Limited about the counterfeit batch of Abhayrab and is involved in the regulatory response to the issue.
Dec 27, 2025 · 15 articles
6 0
Business
A wave of upward revisions to India's FY27 GDP growth forecasts followed stronger-than-expected Q1 FY27 real GDP growth of 7.8 percent, which beat the State Bank of India's 7 percent projection despite the US-Iran war,…
Impact: CGA data showed India's fiscal deficit at 26.8 percent of the full-year target at end-July, better than the prior year.
Aug 25, 2026 · 177 articles
ERGEN INTELLIGENCE
Track India — Drugs Controller General of India live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.